WARNING: This product is for research use only, not for human or veterinary use.
Hodoodo CAT#: H318456
CAS#: 306-07-0
Description: Pargyline hydrochloride is a monoamine oxidase inhibitor with antihypertensive properties. Pargyline selectively inhibits MAO type B, an enzyme catalyzing the oxidative deamination and inactivation of certain catecholamines, such as norepinephrine and dopamine, within the presynaptic nerve terminals. By inhibiting the metabolism of these biogenic amines in the brain, pargyline increases their concentration and binding to postsynaptic receptors.
Hodoodo Cat#: H318456
Name: Pargyline Hydrochloride
CAS#: 306-07-0
Chemical Formula: C11H14ClN
Exact Mass: 0.00
Molecular Weight: 195.690
Elemental Analysis: C, 67.51; H, 7.21; Cl, 18.12; N, 7.16
Synonym: Pargyline Hydrochloride; N-benzyl-N-methylprop-2-yn-1-amine hydrochloride; Eutonyl-ten; N-Methyl-N-propargylbenzylamine hydrochloride; Pargyline HCl; Pargyline;
IUPAC/Chemical Name: N-benzyl-N-methylprop-2-yn-1-amine;hydrochloride
InChi Key: BCXCABRDBBWWGY-UHFFFAOYSA-N
InChi Code: InChI=1S/C11H13N.ClH/c1-3-9-12(2)10-11-7-5-4-6-8-11;/h1,4-8H,9-10H2,2H3;1H
SMILES Code: CN(CC#C)CC1=CC=CC=C1.Cl
Appearance: Solid powder
Purity: >98% (or refer to the Certificate of Analysis)
Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility: Soluble in DMSO, not in water
Shelf Life: >2 years if stored properly
Drug Formulation: This drug may be formulated in DMSO
Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code: 2934.99.9001
More Info:
| Biological target: | |
| In vitro activity: | |
| In vivo activity: |
The following data is based on the product molecular weight 195.69 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.
| Concentration / Solvent Volume / Mass | 1 mg | 5 mg | 10 mg |
|---|---|---|---|
| 1 mM | 1.15 mL | 5.76 mL | 11.51 mL |
| 5 mM | 0.23 mL | 1.15 mL | 2.3 mL |
| 10 mM | 0.12 mL | 0.58 mL | 1.15 mL |
| 50 mM | 0.02 mL | 0.12 mL | 0.23 mL |
| Formulation protocol: | |
| In vitro protocol: | |
| In vivo protocol: |
1: Lowe MC. Hepatotoxicity of pargyline hydrochloride. Proc West Pharmacol Soc.
1978;21:215. PubMed PMID: 693498.
2: Fletcher FW. A unique antihypertensive combination--pargyline hydrochloride
and methyclothiazide: a controlled study of twenty-five patients over a
nine-month period. Curr Ther Res Clin Exp. 1968 Aug;10(8):394-8. PubMed PMID:
4970052.
3: Cantalapiedra Alsedo JL, Del Pozo P. [Clinical experience using pargyline
hydrochloride in the treatment of arterial hypertension]. Rev Clin Esp. 1968 Apr
15;109(1):57-62. Spanish. PubMed PMID: 5738826.
4: Goodsell EB, Krause RA. The effect of prolonged administration of pargyline
hydrochloride (a non-hydrazine monoamine oxidase inhibitor) on glucose
utilization in dogs. Arch Int Pharmacodyn Ther. 1968 Feb;171(2):475-90. PubMed
PMID: 5685843.
5: Lipkin D, Kushnick T. Pargyline hydrochloride poisoning in a child. JAMA. 1967
Jul 3;201(1):135-6. PubMed PMID: 6071697.
6: Hergueta G, García de Guadiana. [Clinical evaluation of pargyline
hydrochloride in the therapy of arterial hypertension]. Rev Esp Cardiol. 1967
Jul;20(3):387-95. Spanish. PubMed PMID: 5613891.
7: Waldmann EB, Nickas G. Pargyline hydrochloride combined with methyclothiazide
in the treatment of hypertension. Ariz Med. 1967 Apr;24(4):343-6. PubMed PMID:
6046398.
8: Sannerstedt R. Hemodynamic effects of pargyline hydrochloride at rest and
during exercise in hypertension. Acta Med Scand. 1967 Jan;181(6):699-706. PubMed
PMID: 4951468.
9: Tcherdakoff P, Leroux-Robert C, Milliez P. [Treatment of arterial hypertension
with pargyline hydrochloride]. Sem Ther. 1966 Dec;42(10):582-6. French. PubMed
PMID: 5996656.
10: Hamm HJ. Pargyline hydrochloride combined with methyclothiazide in the
treatment of essential hypertension. Curr Ther Res Clin Exp. 1966
Aug;8(8):378-83. PubMed PMID: 4958153.
11: Carmichael DB. Aged cheese, pargyline hydrochloride, and paradoxical
hypertension. J Lancet. 1966 May;86(5):235-8. PubMed PMID: 5910166.
12: Breall WS. Treatment of hypertension with a combination of pargyline
hydrochloride and methyclothiazide. J Am Geriatr Soc. 1966 Jan;14(1):85-7. PubMed
PMID: 5901935.
13: Hechart BB, Garimaldi JC, Claria Olmedo RA. [Antihypertensive effect of
pargyline hydrochloride]. Rev Sanid Milit Argent. 1965 Jul-Dec;64(3):140-7.
Spanish. PubMed PMID: 5875067.
14: VAN DYNE JR. PARGYLINE HYDROCHLORIDE IN TREATMENT OF RESISTANT HYPERTENSION.
N Y State J Med. 1965 Jun 15;65:1672-5. PubMed PMID: 14302202.
15: RANGLE RV. THE ANTIHYPERTENSIVE AND HYPOGLYCEMIC EFFECTS OF PARGYLINE
HYDROCHLORIDE. Angiology. 1965 Jun;16:351-4. PubMed PMID: 14294431.
16: BARTOLI AJ. A CLINICAL STUDY OF PARGYLINE HYDROCHLORIDE. West Med Med J West.
1965 Apr;6:110-4 PASSIM. PubMed PMID: 14318405.
17: HUTCHISON JC, KINLAW WB, KRAVITZ B. PARGYLINE HYDROCHLORIDE AND AMINE
HYPERTENSION. Angiology. 1965 Apr;16:187-202. PubMed PMID: 14275865.
18: POLLACK PJ. PARGYLINE HYDROCHLORIDE AND METHYCLOTHIAZIDE COMBINED IN THE
TREATMENT OF HYPERTENSION. Curr Ther Res Clin Exp. 1965 Jan;7:10-8. PubMed PMID:
14246362.
19: Borrero J, Martínez G, Cárdenas C, Restrepo D, Escobar A. [Clinical
evaluation of the hypotensive effect of pargyline hydrochloride and
methyclothiazide]. Antioquia Med. 1965;15(3):159-73. Spanish. PubMed PMID:
5318105.
20: SAWYER NJ, MILLS DM, TROOP RC. EURONYL: PARGYLINE HYDROCHLORIDE. Curr Ther
Res Clin Exp. 1964 Aug;6:538-48. PubMed PMID: 14202214.
